☆ 4.7 Review

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review

JOURNAL OF CLINICAL MEDICINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib

Atsushi Hiraoka et al.

Summary: This study compared the therapeutic efficacy of atezolizumab plus bevacizumab and lenvatinib as first-line treatment for unresectable hepatocellular carcinoma (u-HCC). The results showed that patients who received atezolizumab plus bevacizumab had a better prognosis in terms of PFS and OS compared to those who received lenvatinib.

CANCER MEDICINE (2023)

添加到收藏夹

Review Immunology

The role of PD-1 signaling in health and immune-related diseases

Ru-Yue Chen et al.

Summary: Programmed cell death 1 receptor (PD-1) and its ligands play a crucial role in immune tolerance, immune homeostasis, and immunosuppression. The PD-1 pathway has been implicated in various diseases, including cancer and autoimmune diseases, and PD-1 blockades have been approved for cancer treatment. This comprehensive review focuses on the structure and expression of PD-1, PD-L1, and PD-L2, the diverse biological functions of PD-1 signaling in health and immune-related diseases, and the immune-related adverse events associated with PD-1 and PD-L1 inhibitors.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Outcomes and Management of Immune Checkpoint Inhibitor-Induced Hypothyroidism: A Retrospective Analysis

Allison L. Phillips et al.

Summary: This study retrospectively analyzed the onset, management, and outcomes of hypothyroidism in patients receiving immune checkpoint inhibitors (ICI) treatment. It was found that 19% of patients developed clinical hypothyroidism, requiring thyroid replacement therapy. Patients with clinical hypothyroidism had longer time to disease progression and were more likely to experience additional adverse effects.

ANNALS OF PHARMACOTHERAPY (2022)

添加到收藏夹

Article Hematology

Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma

Yu-Chen Zhang et al.

Summary: In patients with classical Hodgkin lymphoma (cHL) who fail first-line treatment, combining a PD-1 inhibitor with a GVD regimen may be more effective than using GVD alone, particularly in low-risk second-line International Prognostic Score patients. The addition of PD-1 inhibitor in the GVD regimen shows promising results in improving complete remission rate and event-free survival for cHL patients.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Oncology

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

David M. O'Malley et al.

Summary: This phase II trial evaluated the efficacy of dual treatment with balstilimab and zalifrelimab in patients with recurrent and/or metastatic cervical cancer. The results showed promising and durable clinical activity, with favorable tolerability, in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System

Difei Lu et al.

Summary: This article investigates the prevalence and demographic characteristics of immune checkpoint inhibitor (ICI)-related thyroid dysfunction (ICI-TD) and explores the risk factors of poor clinical outcomes. It finds that thyroid dysfunction is common in ICI treatment, especially in combination therapy.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study

Thorsten Fuereder et al.

Summary: The combination of DXT with P demonstrates promising activity in pre-treated R/M HNSCC patients, with some patients experiencing severe adverse effects, but overall the side effects are manageable.

ORAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Kei Sonehara et al.

Summary: This study investigated the predictive factors for the development of immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs). The results revealed that first-line immunotherapy and a score of 0 or 1 on lung immune prognostic index (LIPI) were correlated with the development of irAEs. Patients with irAEs had significantly prolonged survival time compared to those without irAEs.

CANCER MANAGEMENT AND RESEARCH (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Pembrolizumab for previouslytreated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study

Aurelien Marabelle et al.

Summary: The study evaluated the efficacy and safety of Pembrolizumab in patients with advanced anal squamous cell carcinoma, showing that it may be a favorable treatment option for this disease. Efficacy analysis showed an objective response in 11% of patients, while safety analysis revealed treatment-related adverse events in 61% of patients.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Immune checkpoint inhibitor-related thyroid dysfunction

Shintaro Iwama et al.

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Type 1 diabetes related to immune checkpoint inhibitors

Megumi Tachibana et al.

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

添加到收藏夹

Article Oncology

Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea

Junhwan Kim et al.

Summary: This study investigated the effectiveness and safety of pembrolizumab and lenvatinib for recurrent endometrial cancer in a real-world setting. The results showed lower treatment response rate and similar treatment discontinuation rate compared to clinical trials.

GYNECOLOGIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience

Wen-Chi Wu et al.

Summary: This study investigated the efficacy and toxicity of lenvatinib combined with nivolumab in advanced HCC patients. The combination therapy showed higher objective response rate, longer progression-free survival, and overall survival compared to lenvatinib alone. Patients with HBV infection and those who met the REFLECT criteria had a better prognosis.

INVESTIGATIONAL NEW DRUGS (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-Induced Endocrinopathy: A Prospective Study

Artak Labadzhyan et al.

Summary: This study prospectively evaluated the impact of endocrine autoimmunity on the development of immune checkpoint inhibitor (ICI)-induced adverse events (ERAE) and overall survival (OS). ERAE occurred in 14 patients, with hypothyroidism being the most common. The presence of antibodies was significantly associated with ERAE. The presence of ERAE was associated with a more favorable OS.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

添加到收藏夹

Article Dermatology

Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance

Hisashi Uhara et al.

Summary: The study aimed to evaluate the safety of using nivolumab for melanoma patients in Japan. Through the analysis of data from 2008 patients, it was found that although there were some adverse events, there were no additional safety concerns.

JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events

Machiko Kawahira et al.

Summary: This study investigated the safety of resuming immune checkpoint inhibitors (ICIs) after immune-related adverse events (irAEs). The results showed that patients with initial multisystemic irAEs and irAEs of grade ≥2 were more likely to experience relapse or develop new grade ≥2 irAEs after ICI resumption.

PLOS ONE (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis

Tina Mosaferi et al.

Summary: Patients with ICI-associated hypothyroidism have different thyroid hormone dosing requirements than patients with HT. Based on our findings and prior reports, we recommend that in patients with ICI-associated thyroiditis LT4 therapy be started at an initial weight-based dose of 1.45 mcg/[kg center dot day] once serum free thyroxine levels fall below the reference range.

THYROID (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients

Han-Sang Baek et al.

Summary: Thyroid dysfunction caused by ICIs treatment is associated with better survival, especially for patients with newly developed overt or subclinical hypothyroidism.

BMC ENDOCRINE DISORDERS (2022)

添加到收藏夹

Article Oncology

Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment

Jenny Hui Ling Chieng et al.

Summary: This study analyzed the clinical manifestations of endocrine immune-related adverse events, identified factors associated with persistent endocrine dysfunction, and determined the association between endocrine irAEs and survival parameters, emphasizing the importance of early screening and continuous monitoring.

CANCERS (2022)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?

Agnese Barnabei et al.

Summary: Immune checkpoint inhibitors may cause central diabetes insipidus, but there are inconsistencies and a lack of specific guidelines in its diagnosis and management. Endocrinological consultation can assist medical oncologists in treating this side effect, but they are still responsible for early diagnosis and drug management.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline

Eystein S. Husebye et al.

Summary: This guideline provides evidence-based recommendations for the treatment and follow-up of patients with immune checkpoint inhibitor (ICI)-induced endocrine side-effects. A systematic approach to diagnosis, treatment, and follow-up is needed, including baseline tests of endocrine function before each treatment cycle. There is no clear evidence for the benefit of high-dose glucocorticoids in treating endocrine toxicities, with the possible exceptions of severe thyroid eye disease and hypophysitis affecting the visual apparatus. Most endocrine dysfunctions appear to be permanent regardless of ICI discontinuation.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults

Sara J. Schonfeld et al.

Summary: In this cohort study of older adults with melanoma, ICIs were associated with autoimmune-related AEs and other immune-related AEs.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study

Lei Zhao et al.

Summary: Combined therapy with lenvatinib and sintilimab demonstrates significant efficacy and safety in real-world practice for hepatocellular carcinoma, potentially leading to better long-term outcomes compared to lenvatinib monotherapy.

HELIYON (2022)

添加到收藏夹

Article Chemistry, Medicinal

Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma

Hongyan Xu et al.

Summary: The study aimed to investigate the efficacy and safety of preoperative neoadjuvant therapy for resectable stage III lung squamous cell carcinoma. The results showed that the combination of PD-1 inhibitor, nab-PTX, and nedaplatin as neoadjuvant therapy demonstrated remarkable therapeutic efficacy and good safety in patients with lung squamous cell carcinoma.

DRUG DESIGN DEVELOPMENT AND THERAPY (2022)

添加到收藏夹

Article Oncology

Immune checkpoint blockade PD-1 therapy for primary liver cancer: incidence and influencing factors of thyroid dysfunction

Huili Wu et al.

Summary: This study investigated the incidence and influencing factors of thyroid dysfunction (TD) in patients with primary liver cancer (PLC) induced by PD-1 monoclonal antibodies. The results showed a high incidence of TD in PLC patients after receiving PD-1 treatment, with hypothyroidism being the main manifestation type, and it was related to the degree of disease and treatment.

INFECTIOUS AGENTS AND CANCER (2022)

添加到收藏夹

Article Oncology

Application of Electronic Health Record Text Mining: Real-World Tolerability, Safety, and Efficacy of Adjuvant Melanoma Treatments

Sylvia A. van Laar et al.

Summary: This study aimed to retrospectively review the benefits and risks of adjuvant melanoma treatments, finding that immune checkpoint inhibitors were better tolerated than D + T, but the adverse events of D + T were reversible. The study demonstrated that text-mining is a valuable method for collecting real-world data to evaluate melanoma treatments.

CANCERS (2022)

添加到收藏夹

Article Oncology

PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study

Zhe Huang et al.

Summary: This study compared the efficacy and adverse events of immunotherapy and bevacizumab in combination with chemotherapy in patients with advanced lung adenocarcinoma. The study found that immunotherapy was superior to bevacizumab in terms of progression-free survival (PFS), and PD-L1-positive patients had better PFS, overall survival (OS), and overall response rate (ORR). The toxic reactions were manageable in both groups.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Immunology

Pilot Findings on SARS-CoV-2 Vaccine-Induced Pituitary Diseases: A Mini Review from Diagnosis to Pathophysiology

Ach Taieb et al.

Summary: Since the emergence of the COVID-19 pandemic, a massive vaccination campaign has been undertaken worldwide. The COVID-19 vaccine, like other vaccines, can have side effects, including endocrine disorders such as thyroid and pancreas disorders. Pituitary disorders have also been reported following SARS-CoV-2 vaccination, with symptoms appearing within a few days. The limited data available highlights the importance of being vigilant for potential pituitary adverse effects of vaccination.

VACCINES (2022)

添加到收藏夹

Article Medicine, General & Internal

Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma

Halis Kaan Akturk et al.

Summary: This study suggests that immune-related adverse events (irAEs) are associated with treatment response rates and increased survival after immune checkpoint inhibitor (ICI) therapy for advanced melanoma. Specific HLA-DR alleles are associated with different types of irAEs.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Isolated ACTH deficiency following immunization with the BNT162b2 SARS-CoV-2 vaccine: a case report

Shuhei Morita et al.

Summary: This article reports the first case of isolated adrenocorticotropic hormone (ACTH) deficiency potentially associated with COVID-19 immunization. It highlights the importance of adjuvants in mRNA vaccines in inducing endocrinological adverse effects through disturbance of the autoimmune system.

BMC ENDOCRINE DISORDERS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases

Thomas U. Schulz et al.

Summary: This dataset contains demographic, clinical, and health-related quality of life data from 2905 patients, including cancer patients after immune checkpoint inhibitor cessation and patients with autoimmune diseases. The data provide a basis for further research on the quality of life, autoimmunity, and therapy of autoimmunity among cancer patients after immune checkpoint inhibitor cessation and patients with different autoimmune diseases.

DATA IN BRIEF (2022)

添加到收藏夹

Article Oncology

Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II

Xin Liu et al.

Summary: This study aimed to evaluate the safety and efficacy of combining pegylated liposomal doxorubicin (PLD) and ifosfamide (IFO) as the first-line treatment for advanced or metastatic soft-tissue sarcoma (STS). The results showed that the combination therapy of PLD and IFO is effective and well-tolerated in treating STS.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Immunology

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation

Alan Kennedy et al.

Summary: CD28 and CTLA-4 play important roles in regulating T cell immunity. The study found that CTLA-4 captures ligands through transendocytosis, and CD80 leads to ubiquitination and degradation of CTLA-4, while CD86 allows CTLA-4 to detach and recycle back to the cell surface. Clinically relevant mutations disrupt CD86 transendocytosis and are associated with autoimmune diseases.

NATURE IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study

Jingjing Qu et al.

Summary: This study demonstrates that adding PD-L1 inhibitors to chemotherapy can significantly improve progression-free survival (PFS) and overall survival (OS) in patients with extensive-stage small-cell lung cancer (ES-SCLC), and shows its safety without additional adverse events.

JOURNAL OF ONCOLOGY (2022)

添加到收藏夹

Review Medicine, General & Internal

A Diagnostic of Acquired Hemophilia Following PD1/PDL1 Inhibitors in Advanced Melanoma: The Experience of Two Patients and a Literature Review

Antonio Gidaro et al.

Summary: Acquired hemophilia A is a rare bleeding disorder caused by specific autoantibodies against factor VIII. Immunotherapy, especially immune checkpoint inhibitors, can lead to autoimmune-related adverse effects, including AHA. In this report, two cases of AHA developed during anti-PD-1 immunotherapy were successfully treated with activated FVII and rituximab.

DIAGNOSTICS (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study br

Yoko Ueba et al.

Summary: Combination therapy with immune checkpoint inhibitors (ICIs) may delay the onset of thyroid immune-related adverse events (irAEs).

ENDOCRINE JOURNAL (2022)

添加到收藏夹

Article Oncology

Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors

Joana Lima Ferreira et al.

Summary: Immune-checkpoint inhibitors can lead to thyroid function abnormalities, including primary and central hypothyroidism, which may be predictive of improved clinical outcomes and response to ICI treatment across different types of neoplasms.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis

Nuttapong Ngamphaiboon et al.

Summary: In Thai cancer patients treated with immune-checkpoint inhibitors (ICIs), immune-related adverse events (irAEs) were commonly observed, mainly low-grade and manageable. Re-occurrence of irAEs after re-challenging with ICIs was not uncommon. Patients with irAEs may have significantly longer overall survival (OS) compared to those without irAEs.

BMC CANCER (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data

Abdulaali R. Almutairi et al.

Summary: In older patients with advanced melanoma, there was no statistically significant difference in the risk of ir-hypothyroidism between users of ipilimumab and nivolumab. Patients treated with ipilimumab or pembrolizumab may have a lower risk of ir-hypothyroidism compared to nivolumab users.

EXPERT OPINION ON DRUG SAFETY (2021)

添加到收藏夹

Article Oncology

First-line atezolizumab monotherapy in patients with advanced BRAFV600 wild-type melanoma

Sergio Jobim de Azevedo et al.

Summary: This study evaluated the efficacy and safety of atezolizumab as a first-line treatment for advanced melanoma, showing that it has antitumor activity and is relatively safe and well-tolerated in patients.

PIGMENT CELL & MELANOMA RESEARCH (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy

L. Brilli et al.

Summary: This study aimed to identify predictive factors for the development of thyroid dysfunction during immunotherapy in patients with metastatic or unresectable advanced cancers treated with immune checkpoint inhibitors. Results showed that pre-treatment serum TSH and ATAbs levels may help to identify patients at high risk for primary thyroid dysfunction. This suggests guidance for appropriate screening and management of thyroid dysfunctions in patients undergoing ICIs treatment.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2021)

添加到收藏夹

Article Oncology

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

Caroline Robert et al.

Summary: The long-term safety and efficacy of pembrolizumab in treating melanoma were analyzed in a large population, showing no new toxicity signals after a lengthy follow-up period. The efficacy of pembrolizumab was similar regardless of the presence of immune-mediated adverse events or the use of systemic corticosteroids.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Immunology

Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer

Yuwen Zhou et al.

Summary: In advanced NSCLC patients treated with PD-1 inhibitors, the presence of TFA-irAEs was associated with longer overall survival and progression free survival. Thyroid function abnormality may serve as a biomarker for antitumor immune response.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Article Oncology

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

David F. McDermott et al.

Summary: First-line pembrolizumab monotherapy demonstrated promising antitumor activity in patients with nccRCC, showing similar efficacy and safety profile to other tumor types.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors

Jennifer L. Leddon et al.

Summary: The study aimed to determine whether adding anti-PD-1/PD-L1 therapy to standard HNSCC treatment increases the risk of hypothyroidism. Results showed no significant difference in hypothyroidism rates between the two groups, and multivariate logistic regression found no significant difference in hypothyroidism based on age, sex, or BMI.

LARYNGOSCOPE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?

Izabela Chmielewska et al.

Summary: The study aimed to assess the occurrence and nature of immune-related endocrine adverse events (irAEs) among patients with NSCLC treated with nivolumab. Results showed that some patients developed thyroid dysfunction and other irAEs, but no relationship was found between patients with irAE and better cancer prognosis.

PLOS ONE (2021)

添加到收藏夹

Article Oncology

Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection

Akram Alkrekshi et al.

Summary: This study retrospectively analyzed patients with hepatitis C virus (HCV) infection who received ICIs treatment from January 2012 to December 2019. The adverse event rates in these patients were comparable to those reported in clinical trials for patients without HCV.

ONCOLOGIST (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy

C. Luongo et al.

Summary: ICIs are monoclonal antibodies that boost the immune response against cancer cells, but they can also lead to endocrine immune-related adverse events (irAEs). This study found that baseline TSH levels above 1.67 mIU/L and positive anti-thyroid antibodies are risk factors for thyroid irAEs. Patients with thyroid irAEs had better survival outcomes than those who remained euthyroid.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2021)

添加到收藏夹

Article Oncology

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors

Luisa Maria Griewing et al.

Summary: Immune checkpoint inhibitors (ICI) are standard treatments for various tumors, but early detection of immune-related adverse events (irAE) is crucial. This study found that questionnaires can help detect gastrointestinal, lung, endocrine, or skin irAE, but not hepatic irAE. Weight change and insomnia questions may increase irAE detection rate.

BMC CANCER (2021)

添加到收藏夹

Article Oncology

Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer

Wei Yu et al.

Summary: The study found that regorafenib combined with toripalimab has a promising effect in the third-line and beyond treatment of advanced colorectal cancer, with surgical resection of primary lesions potentially having a positive impact on this combination therapy. The treatment-related adverse reactions in combined therapy are tolerable to a certain extent.

JOURNAL OF ONCOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Christopher A. Muir et al.

Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with different subtypes of thyroid immune-related adverse events having unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer progression free survival and overall survival, while hypothyroidism showed no association with cancer outcomes. Multiple distinct phenotypes of thyroid irAEs suggest potentially different etiologies for thyrotoxicosis and hypothyroidism.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Oncology

A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study)

Hongtao Duan et al.

Summary: This study evaluated the efficacy and safety of neoadjuvant therapy with sintilimab in combination with chemotherapy for esophageal cancer. The results showed that this treatment was safe and led to a high pathological complete response rate, suggesting further testing is warranted.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Endocrine toxicities of immune checkpoint inhibitors

Jordan J. Wright et al.

Summary: Immune checkpoint inhibitors (ICIs) have become a cornerstone of cancer therapeutics, but can also cause toxicities in various organs known as immune-related adverse events. ICIs can lead to endocrinopathies involving the thyroid, pituitary, adrenal glands, and pancreas, which are common and sometimes fatal.

NATURE REVIEWS ENDOCRINOLOGY (2021)

添加到收藏夹

Article Cell Biology

CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice

Yoshinori Yasuda et al.

Summary: The study found that CD4(+) T cells play a critical role in the development of destructive thyroiditis, and depletion of CD4(+) T cells can completely prevent the occurrence of the disease.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors

Jee Hee Yoon et al.

Summary: Thyroid immune-related adverse events are common in cancer patients treated with PD-1/PD-L1 inhibitors, with the majority of patients being able to recover normal thyroid function. However, some patients may progress to overt hypothyroidism and require thyroid hormone replacement therapy. Risk factors for developing overt hypothyroidism include higher baseline thyroid stimulating hormone levels and longer duration of therapy.

ENDOCRINOLOGY AND METABOLISM (2021)

添加到收藏夹

Article Oncology

Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance

Nobuyuki Yamamoto et al.

Summary: Postmarketing surveillance of Japanese patients with unresectable, previously treated, advanced or recurrent non-small-cell lung cancer treated with nivolumab showed a higher incidence of treatment-related adverse events, but the overall safety profile was similar to that in clinical trials and no new safety signals were identified.

CANCER SCIENCE (2021)

添加到收藏夹

Article Oncology

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab

Vicky Makker et al.

Summary: The combination of lenvatinib plus pembrolizumab in the treatment of advanced endometrial carcinoma following prior systemic therapy showed efficacy, with manageable safety profile and common adverse reactions occurring within the first 10 weeks of treatment. Most adverse reactions were managed through study drug dose modifications and concomitant medications.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Development of Skin Rash Predicts Outcome of Anti-PD-1-and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis

Karin Mayer et al.

Summary: This study found that the development of immune-related skin rash was associated with a favorable treatment outcome, suggesting its potential feasibility as a predictive surrogate marker.

ONCOLOGY RESEARCH AND TREATMENT (2021)

添加到收藏夹

Review Oncology

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer

A. Trullas et al.

Summary: The European Commission approved pembrolizumab for the first-line treatment of MSI-H or dMMR metastatic colorectal cancer in adults, leading to a significant improvement in progression-free survival compared to standard of care.

ESMO OPEN (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Christopher A. Muir et al.

Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with distinct phenotypes of thyroid irAEs showing unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer survival outcomes, while no association was found between hypothyroidism and cancer outcomes.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase

Xuefeng Bai et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)

添加到收藏夹

Article Oncology

Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study

Norio Okada et al.

BRITISH JOURNAL OF CANCER (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Immunoassay Interference on Thyroid Function Tests During Treatment with Nivolumab

Rosa Maria Paragliola et al.

THYROID (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report

Susumu Kurihara et al.

JOURNAL OF DIABETES INVESTIGATION (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients

Edwin A. Basak et al.

THYROID (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer

Christopher A. Muir et al.

THYROID (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study

X. Bai et al.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction

Anna Olsson-Brown et al.

ENDOCRINE CONNECTIONS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A decade of immune-checkpoint inhibitors in cancer therapy

Caroline Robert

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Review Endocrinology & Metabolism

Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review

Maria Stelmachowska-Banas et al.

ENDOCRINE CONNECTIONS (2020)

添加到收藏夹

Article Medicine, General & Internal

Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up

Manon Levy et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Article Oncology

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

Marion Allouchery et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Review Endocrinology & Metabolism

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints

Lee-Shing Chang et al.

ENDOCRINE REVIEWS (2019)

添加到收藏夹

Letter Endocrinology & Metabolism

T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors

Sho Yoneda et al.

DIABETES CARE (2019)

添加到收藏夹

Article Endocrinology & Metabolism

BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION

Rena M. Pollack et al.

ENDOCRINE PRACTICE (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies

Silvia Martina Ferrari et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Article Oncology

The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders

Chanjuan Ma et al.

CANCER IMMUNOLOGY RESEARCH (2019)

添加到收藏夹

Review Endocrinology & Metabolism

Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis

H. K. Akturk et al.

DIABETIC MEDICINE (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis

Alexander Faje et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)

添加到收藏夹

Review Immunology

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer

Weiting Qin et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Article Oncology

Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer

Yukihiro Toi et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy

Megu Yamaguchi Baden et al.

DIABETOLOGY INTERNATIONAL (2019)

添加到收藏夹

Review Endocrinology & Metabolism

Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature

Alessandro Brancatella et al.

EUROPEAN THYROID JOURNAL (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

Angeliki Stamatouli et al.

DIABETES (2018)

添加到收藏夹

Letter Oncology

Immunotherapy-induced Addison's disease: A rare, persistent and potentially lethal side-effect

S. Hescot et al.

EUROPEAN JOURNAL OF CANCER (2018)

添加到收藏夹

Article Oncology

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis

Romualdo Barroso-Sousa et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations

Judith A. Seidel et al.

FRONTIERS IN ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Shiro Kimbara et al.

CANCER SCIENCE (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

Priyanka C. Iyer et al.

THYROID (2018)

添加到收藏夹

Letter Endocrinology & Metabolism

Histology of Nivolumab-Induced Thyroiditis

Christina Neppl et al.

THYROID (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma

Trevor E. Angell et al.

GENES & DISEASES (2018)

添加到收藏夹

Review Endocrinology & Metabolism

Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms

Danae A. Delivanis et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

J. Weber et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy

Hyunju Lee et al.

CANCER IMMUNOLOGY RESEARCH (2017)

添加到收藏夹

Article Oncology

Nivolumab induced myxedema crisis

Uqba Khan et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Tremelimumab-Induced Graves Hyperthyroidism

Earn H. Gan et al.

EUROPEAN THYROID JOURNAL (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma

Anne-Cecile Paepegaey et al.

JOURNAL OF THE ENDOCRINE SOCIETY (2017)

添加到收藏夹

Article Endocrinology & Metabolism

RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB

Grenye O'Malley et al.

ENDOCRINE PRACTICE (2017)

添加到收藏夹

Article Pathology

Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series

Patrizio Caturegli et al.

AMERICAN JOURNAL OF PATHOLOGY (2016)

添加到收藏夹

Article Pathology

Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1) Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors

Shingo Inaguma et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline

Stefan R. Bornstein et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)

添加到收藏夹

Review Medicine, General & Internal

Hyperthyroidism

Simone De Leo et al.

LANCET (2016)

添加到收藏夹

Article Immunology

Low programmed cell death-1 (PD-1) expression in peripheral CD4+ T cells in Japanese patients with autoimmune type 1 diabetes

R. Fujisawa et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)

添加到收藏夹

Article Endocrinology & Metabolism

Rabphilin-3A as a Targeted Autoantigen in Lymphocytic Infundibulo-neurohypophysitis

Shintaro Iwama et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)

添加到收藏夹

Article Endocrinology & Metabolism

Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies

Steven Orlov et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)

添加到收藏夹

Article Oncology

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Alexander M. M. Eggermont et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Review Biochemistry & Molecular Biology

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

Kim C. Ohaegbulam et al.

TRENDS IN MOLECULAR MEDICINE (2015)

添加到收藏夹

Article Endocrinology & Metabolism

Pituitary Dysfunction in Granulomatosis With Polyangiitis: The Mayo Clinic Experience

Ekta Kapoor et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)

添加到收藏夹

Article Endocrinology & Metabolism

Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma

Alexander T. Faje et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)

添加到收藏夹

Article Cell Biology

Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

Shintaro Iwama et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

添加到收藏夹

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Hematology

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Mojgan Ahmadzadeh et al.

BLOOD (2009)

添加到收藏夹

Review Immunology

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

Arlene H. Sharpe et al.

NATURE IMMUNOLOGY (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.